HRP20201729T1 - Antitijela protiv aktivina a i njihova primjena - Google Patents
Antitijela protiv aktivina a i njihova primjena Download PDFInfo
- Publication number
- HRP20201729T1 HRP20201729T1 HRP20201729TT HRP20201729T HRP20201729T1 HR P20201729 T1 HRP20201729 T1 HR P20201729T1 HR P20201729T T HRP20201729T T HR P20201729TT HR P20201729 T HRP20201729 T HR P20201729T HR P20201729 T1 HRP20201729 T1 HR P20201729T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- antibody
- binding fragment
- gdf8
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (5)
1. Izolirano antitijelo ili njegov fragment koji se vezuje za antigen koje se specifično vezuje za aktivin A s konstantom ravnoteže disocijacije vezivanja (KD) manjom od 5 pM, opcionalno s KD-om manjom od 4 pM, izmjereno testom rezonancije površinskih plazmona pri temperaturi od 25 °C, naznačeno time, što antitijelo ili fragment koji se vezuje za antigen obuhvaća: HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domene koje imaju aminokiselinske sekvence SEQ ID NO: 164-166-168-148-150-152.
2. Izolirano antitijelo ili njegov fragment koji se vezuje za antigen prema patentnom zahtjevu 1, naznačeno time, što antitijelo ili fragment koji se vezuje za antigen uključuje: (a) HCVR koji ima aminokiselinsku sekvencu SEQ ID NO: 162; i (b) LCVR koji ima aminokiselinsku sekvencu SEQ ID NO: 146.
3. Farmaceutski pripravak koji obuhvaća antitijelo ili fragment koji se vezuje za antigen prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 i farmaceutski prihvatljivi nosač ili razrjeđivač.
4. Farmaceutski pripravak prema patentnom zahtjevu 3, koji dodatno obuhvaća antagonist GDF8, opcionalno naznačen time, što je antagonist GDF8 odabran iz skupine koja se sastoji od fuzijskog proteina koji inhibira GDF8, anti-GDF8 antitijela i fragmenta anti-GDF8 antitijela koji se vezuje za antigen.
5. Antitijelo ili njegov fragment koji se vezuje za antigen prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 ili farmaceutski pripravak prema patentnom zahtjevu 3 ili patentnom zahtjevu 4 za primjenu u liječenju, sprječavanju ili ublažavanju bolesti ili poremećaja karakteriziranog smanjenjem mišićne mase ili snage, naznačeno time, što je bolest ili poremećaj karakteriziran smanjenjem mišićne mase ili snage odabran iz skupine koja se sastoji od sarkopenije, kaheksije, ozljede mišića, propadanja/atrofije mišića, raka, pretilosti, dijabetesa, artritisa, multiple skleroze, mišićne distrofije, amiotrofične lateralne skleroze, Parkinsonove bolesti, osteoporoze, osteoartritisa, osteopenije i metaboličkog sindroma.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361859926P | 2013-07-30 | 2013-07-30 | |
| US201361864036P | 2013-08-09 | 2013-08-09 | |
| US201361911834P | 2013-12-04 | 2013-12-04 | |
| US201361913885P | 2013-12-09 | 2013-12-09 | |
| PCT/US2014/048957 WO2015017576A1 (en) | 2013-07-30 | 2014-07-30 | Anti-activin a antibodies and uses thereof |
| EP14750421.1A EP3027209B1 (en) | 2013-07-30 | 2014-07-30 | Anti-activin a antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201729T1 true HRP20201729T1 (hr) | 2020-12-25 |
Family
ID=52427866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201729TT HRP20201729T1 (hr) | 2013-07-30 | 2014-07-30 | Antitijela protiv aktivina a i njihova primjena |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US9718881B2 (hr) |
| EP (4) | EP4062937A1 (hr) |
| JP (6) | JP6581085B2 (hr) |
| KR (2) | KR102440044B1 (hr) |
| CN (2) | CN105592858B (hr) |
| AU (2) | AU2014296243B2 (hr) |
| BR (1) | BR112016002164B1 (hr) |
| CA (1) | CA2920071C (hr) |
| CL (1) | CL2016000251A1 (hr) |
| CY (1) | CY1123788T1 (hr) |
| DK (1) | DK3027209T3 (hr) |
| EA (1) | EA037926B1 (hr) |
| ES (1) | ES2827673T3 (hr) |
| HR (1) | HRP20201729T1 (hr) |
| HU (1) | HUE052518T2 (hr) |
| IL (2) | IL243822B (hr) |
| LT (1) | LT3027209T (hr) |
| MX (2) | MX371498B (hr) |
| PH (1) | PH12016500182B1 (hr) |
| PT (1) | PT3027209T (hr) |
| RS (1) | RS61124B1 (hr) |
| SG (1) | SG11201600731WA (hr) |
| SI (1) | SI3027209T1 (hr) |
| SM (1) | SMT202000643T1 (hr) |
| TW (2) | TW201920262A (hr) |
| UY (1) | UY35682A (hr) |
| WO (1) | WO2015017576A1 (hr) |
| ZA (1) | ZA201601294B (hr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EP2781222B1 (en) | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| JP2010539236A (ja) | 2007-09-18 | 2010-12-16 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用 |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP3290439B1 (en) | 2009-06-12 | 2020-09-02 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| JP6177249B2 (ja) | 2011-11-14 | 2017-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法 |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| WO2016145206A1 (en) | 2015-03-10 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Aseptic piercing system and method |
| EA039118B1 (ru) * | 2015-04-01 | 2021-12-07 | Ридженерон Фармасьютикалз, Инк. | Способ лечения прогрессирующей оссифицирующей фибродисплазии |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| EP3288976B1 (en) | 2015-04-29 | 2020-04-08 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| TW202417497A (zh) * | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| US20180008672A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| CN116531490A (zh) | 2016-07-15 | 2023-08-04 | 阿塞勒隆制药公司 | 用于治疗肺高血压的组合物和方法 |
| CA3039074A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Compositions and method for treating kidney disease |
| EP3525820A4 (en) * | 2016-10-17 | 2020-09-16 | Vanderbilt University | ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS AND THEIR USE METHODS |
| CN119241685A (zh) * | 2016-11-10 | 2025-01-03 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| ES2919934T3 (es) | 2017-05-05 | 2022-07-29 | Regeneron Pharma | Autoinyector y procedimientos de uso relacionados |
| CA3063588A1 (en) * | 2017-06-01 | 2018-12-06 | Regeneron Pharmaceuticals, Inc. | Human antibodies to bet v 1 and methods of use thereof |
| WO2023154672A2 (en) * | 2022-02-14 | 2023-08-17 | Ohio University | Methods for regulating muscle performance using fat specific protein 27 (fsp27) compositions |
| DE102018103302A1 (de) * | 2018-02-14 | 2019-08-14 | Noonee Ag | Tragbare Sitzhaltungshilfevorrichtung |
| KR20200128125A (ko) | 2018-03-01 | 2020-11-11 | 리제너론 파아마슈티컬스, 인크. | 신체 조성을 변경하기 위한 방법 |
| LT3773713T (lt) | 2018-04-06 | 2025-08-25 | Regeneron Pharmaceuticals, Inc. | Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija |
| US11419319B2 (en) | 2018-06-13 | 2022-08-23 | Regeneran Pharmaceuticals, Inc. | Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation |
| MX2021007394A (es) | 2018-12-18 | 2021-07-15 | Regeneron Pharma | Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a. |
| AU2020284038B2 (en) | 2019-05-30 | 2026-05-14 | Acceleron Pharma Inc. | ActRII-binding proteins and uses thereof |
| IL294611B1 (en) | 2020-01-08 | 2026-05-01 | Regeneron Pharmaceuticals Inc | Treatment of fibrodysplasia ossificans progressive |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| JP2023519100A (ja) | 2020-02-11 | 2023-05-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ａｃｖｒ１抗体およびその使用 |
| EP4142769A4 (en) | 2020-04-28 | 2024-05-15 | Acceleron Pharma Inc. | ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION |
| IL299103A (en) | 2020-06-18 | 2023-02-01 | Regeneron Pharma | Formulations of activin A antibody and methods of its use |
| CA3177918A1 (en) | 2020-07-01 | 2022-01-06 | Amanda ATANASIO | Methods of treating allergy using anti-bet v 1 antibodies |
| JP2023539107A (ja) * | 2020-08-20 | 2023-09-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アクチビンａアンタゴニストによる心機能障害及びｃｏｖｉｄ－１９の予防及び治療方法 |
| AU2021377176A1 (en) * | 2020-11-11 | 2023-06-22 | Hq Han | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof |
| WO2023022968A2 (en) * | 2021-08-16 | 2023-02-23 | Acceleron Pharma Inc. | Compositions and methods for treating renal diseases or conditions |
| EP4419553A1 (en) | 2021-10-18 | 2024-08-28 | BYOMass Inc. | Anti-activin a antibodies, compositions and uses thereof |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| EP4472733A1 (en) | 2022-01-31 | 2024-12-11 | BYOMass Inc. | Myeloproliferative conditions |
| TWI819587B (zh) * | 2022-04-29 | 2023-10-21 | 洪慧妤 | 用於預防癌症所引發的肌少症之組合物及組合物於製造供預防癌症所引發之肌少症食品的用途 |
| KR20250075642A (ko) | 2022-09-21 | 2025-05-28 | 리제너론 파아마슈티컬스, 인크. | 비만, 당뇨병 및 간 기능 장애를 치료하는 방법 |
| KR20260025363A (ko) | 2023-06-16 | 2026-02-24 | 리제너론 파아마슈티컬스, 인크. | 의료 디바이스 패키징 및 관련 방법 |
| CN116990523A (zh) * | 2023-06-30 | 2023-11-03 | 重庆医科大学 | 骨形态蛋白-9作为生物标志物在脓毒血症诊断、预后、疗效评估及治疗中的用途 |
| WO2025075970A1 (en) | 2023-10-02 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Drug delivery device safety system |
| US20260000758A1 (en) * | 2024-06-28 | 2026-01-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof |
| WO2026037938A1 (en) | 2024-08-16 | 2026-02-19 | Protuoso Pte. Ltd. | Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
| SK722002A3 (en) | 1999-07-20 | 2003-02-04 | Pharmexa As | Method for down-regulating GDF-8 activity |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| JP5110877B2 (ja) | 2003-06-02 | 2012-12-26 | ワイス・エルエルシー | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
| CN1902221A (zh) | 2003-12-31 | 2007-01-24 | 先灵-普劳有限公司 | 基于中和表位的生长增强疫苗 |
| US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| MX2007000976A (es) | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| EP1877075A4 (en) | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| ES2533464T3 (es) | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anticuerpos anti-miostatina |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| CN101370511B (zh) * | 2005-11-23 | 2015-07-01 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| EP1968621A2 (en) | 2005-12-06 | 2008-09-17 | Amgen Inc. | Uses of myostatin antagonists |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| PL2066695T3 (pl) | 2006-09-05 | 2013-08-30 | Lilly Co Eli | Przeciwciała przeciwko miostatynie |
| CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AR069165A1 (es) | 2007-11-05 | 2010-01-06 | Novartis Ag | Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| NZ627111A (en) * | 2008-11-26 | 2015-10-30 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| CA2993053A1 (en) | 2009-04-27 | 2010-11-04 | Novartis Ag | Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| JP6177249B2 (ja) * | 2011-11-14 | 2017-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法 |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| KR20200128125A (ko) * | 2018-03-01 | 2020-11-11 | 리제너론 파아마슈티컬스, 인크. | 신체 조성을 변경하기 위한 방법 |
-
2014
- 2014-07-28 TW TW107147614A patent/TW201920262A/zh unknown
- 2014-07-28 TW TW103125622A patent/TWI655207B/zh active
- 2014-07-30 LT LTEP14750421.1T patent/LT3027209T/lt unknown
- 2014-07-30 CN CN201480049484.7A patent/CN105592858B/zh active Active
- 2014-07-30 SI SI201431693T patent/SI3027209T1/sl unknown
- 2014-07-30 AU AU2014296243A patent/AU2014296243B2/en active Active
- 2014-07-30 SG SG11201600731WA patent/SG11201600731WA/en unknown
- 2014-07-30 EA EA201690243A patent/EA037926B1/ru unknown
- 2014-07-30 EP EP22171329.0A patent/EP4062937A1/en active Pending
- 2014-07-30 CN CN202111054074.XA patent/CN113845594A/zh active Pending
- 2014-07-30 UY UY35682A patent/UY35682A/es active IP Right Grant
- 2014-07-30 MX MX2016001394A patent/MX371498B/es active IP Right Grant
- 2014-07-30 BR BR112016002164-9A patent/BR112016002164B1/pt active IP Right Grant
- 2014-07-30 ES ES14750421T patent/ES2827673T3/es active Active
- 2014-07-30 EP EP20176858.7A patent/EP3730151A1/en active Pending
- 2014-07-30 EP EP14750421.1A patent/EP3027209B1/en active Active
- 2014-07-30 KR KR1020217033330A patent/KR102440044B1/ko active Active
- 2014-07-30 HR HRP20201729TT patent/HRP20201729T1/hr unknown
- 2014-07-30 PH PH1/2016/500182A patent/PH12016500182B1/en unknown
- 2014-07-30 RS RS20201414A patent/RS61124B1/sr unknown
- 2014-07-30 PT PT147504211T patent/PT3027209T/pt unknown
- 2014-07-30 EP EP22171327.4A patent/EP4059520A1/en active Pending
- 2014-07-30 SM SM20200643T patent/SMT202000643T1/it unknown
- 2014-07-30 KR KR1020167005280A patent/KR102315694B1/ko active Active
- 2014-07-30 CA CA2920071A patent/CA2920071C/en active Active
- 2014-07-30 JP JP2016531870A patent/JP6581085B2/ja active Active
- 2014-07-30 US US14/447,444 patent/US9718881B2/en active Active
- 2014-07-30 MX MX2020001201A patent/MX379446B/es unknown
- 2014-07-30 DK DK14750421.1T patent/DK3027209T3/da active
- 2014-07-30 HU HUE14750421A patent/HUE052518T2/hu unknown
- 2014-07-30 WO PCT/US2014/048957 patent/WO2015017576A1/en not_active Ceased
-
2016
- 2016-01-28 IL IL24382216A patent/IL243822B/en active IP Right Grant
- 2016-01-29 CL CL2016000251A patent/CL2016000251A1/es unknown
- 2016-02-25 ZA ZA2016/01294A patent/ZA201601294B/en unknown
-
2017
- 2017-06-29 US US15/637,867 patent/US10526403B2/en active Active
-
2019
- 2019-08-28 JP JP2019155139A patent/JP6923602B2/ja active Active
- 2019-10-27 IL IL270218A patent/IL270218B/en active IP Right Grant
-
2020
- 2020-02-07 AU AU2020200892A patent/AU2020200892B2/en active Active
- 2020-07-10 US US16/926,481 patent/US20210163583A1/en not_active Abandoned
- 2020-12-01 CY CY20201101138T patent/CY1123788T1/el unknown
-
2021
- 2021-07-28 JP JP2021122976A patent/JP7440464B2/ja active Active
-
2022
- 2022-06-29 JP JP2022104218A patent/JP7496387B2/ja active Active
- 2022-08-09 JP JP2022126761A patent/JP7589200B2/ja active Active
- 2022-11-28 US US18/059,315 patent/US20230312699A1/en active Pending
-
2024
- 2024-11-12 JP JP2024197067A patent/JP2025024066A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021245146B2 (en) | Influenza A virus specific antibodies | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| HRP20230844T1 (hr) | Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe | |
| HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2011528901A5 (hr) | ||
| PH12014500089A1 (en) | Antibodies that bind to ox40 and their uses | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2017500018A5 (hr) | ||
| JP2011157378A5 (hr) | ||
| NZ630433A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| JP2016532693A5 (hr) | ||
| JP2011219478A5 (hr) | ||
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| JP2015535691A5 (hr) | ||
| JP2016029056A5 (hr) | ||
| JP2014205674A5 (hr) | ||
| HRP20210113T1 (hr) | Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije | |
| WO2012059598A3 (en) | Methods of treating rheumatoid arthritis using il-17 antagonists | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| JP2009273466A5 (hr) |